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TNFA -308G>A in two international population-based cohorts
and risk of asthma
Abstract
Genetic association studies have related the tumour necrosis factor-alpha gene (TNFA) guanine to
adenine substitution of nucleotide -308 (-308G>A) polymorphism to increased risk of asthma, but
results are inconsistent. The aim of the present study was to test whether two single-nucleotide
polymorphisms, of TNFA and of the lymphotoxin-alpha gene (LTA), are associated with asthma,
bronchial hyperresponsiveness and atopy in adults, by combining the results of two large
population-based multicentric studies and conducting a meta-analysis of previously published studies.
The European Community Respiratory Health Survey (ECRHS) and Swiss Cohort Study on Air
Pollution and Lung and Heart Diseases in Adults (SAPALDIA) used comparable protocols, including
questionnaires for respiratory symptoms and measures of lung function and atopy. DNA samples from
11,136 participants were genotyped at TNFA -308 and LTA 252. Logistic regression employing fixed
and random effects models and nonparametric techniques were used. The prevalence of asthma was 6%.
The TNFA -308G>A polymorphism was associated with increased asthma prevalence and with
bronchial hyperresponsiveness. No consistent association was found for atopy. The LTA 252A>G
polymorphism was not associated with any of the outcomes. A meta-analysis of 17 studies showed an
increased asthma risk for the TNFA -308 adenine allele. The tumour necrosis factor-alpha gene
nucleotide -308 polymorphism is associated with a moderately increased risk of asthma and bronchial
hyperresponsiveness, but not with atopy. These results are supported by a meta-analysis of previously
published studies.
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ABSTRACT: Genetic association studies have related the tumour necrosis factor-a gene (TNFA)
guanine to adenine substitution of nucleotide -308 (-308G.A) polymorphism to increased risk of
asthma, but results are inconsistent. The aim of the present study was to test whether two single-
nucleotide polymorphisms, of TNFA and of the lymphotoxin-a gene (LTA), are associated with
asthma, bronchial hyperresponsiveness and atopy in adults, by combining the results of two large
population-based multicentric studies and conducting a meta-analysis of previously published
studies.
The European Community Respiratory Health Survey (ECRHS) and Swiss Cohort Study on Air
Pollution and Lung and Heart Diseases in Adults (SAPALDIA) used comparable protocols,
including questionnaires for respiratory symptoms and measures of lung function and atopy. DNA
samples from 11,136 participants were genotyped at TNFA -308 and LTA 252. Logistic regression
employing fixed and random effects models and nonparametric techniques were used.
The prevalence of asthma was 6%. The TNFA -308G.A polymorphism was associated with
increased asthma prevalence and with bronchial hyperresponsiveness. No consistent association
was found for atopy. The LTA 252A.G polymorphism was not associated with any of the
outcomes. A meta-analysis of 17 studies showed an increased asthma risk for the TNFA -308
adenine allele.
The tumour necrosis factor-a gene nucleotide -308 polymorphism is associated with a
moderately increased risk of asthma and bronchial hyperresponsiveness, but not with atopy.
These results are supported by a meta-analysis of previously published studies.
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A
sthma is a complex disease with both
genetic and environmental components.
It is characterised by obstruction of the
airways of the lung and is related to atopy and
bronchial hyperresponsiveness (BHR). Several
chromosome regions and candidate genes have
been associated with asthma, although the
individual genes identified to date exhibit only
modest effects and an unknown pattern of
inheritance [1–3].
Tumour necrosis factor (TNF) is a potent pro-
inflammatory cytokine involved in the inflamma-
tion of asthmatic airways [4]. It is located within
the class III region of the major histocompatibility
complex (MHC) region on chromosome 6p21.3
[5], which has previously been linked to asthma
in various genome screens [1, 3, 6]. The TNF-a
gene (TNFA) and lymphotoxin-a (LT-a) gene
(LTA, also called TNFB) are members of the
TNF superfamily. TNFA plays an important role
in generating and maintaining inflammatory
responses and airway hyperreactivity [7, 8].
TNF-a has been found in increased concentra-
tions in the airways [8] and bronchoalveolar
lavage fluid of asthmatic patients [9]. Moreover,
the TNF-a secretory response to allergens differs
between atopic and nonatopic subjects [10]. LTA
is located closely upstream of TNFA, and both
exhibit similar biological activity [11].
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Polymorphisms in the two genes may affect the levels of TNF in
the airways. The TNFA guanine (G) to adenine (A) substitution
of nucleotide -308 (-308G.A) polymorphism, located in the
promoter region of TNFA, has been associated with increased
secretion and promoter activity [12]. The LTA 252A.G
polymorphism, located in the first intron of LTA seems to be
associated with high LT-a production [13]. The TNFA -308A and
LTA 252G alleles have been positively associated with asthma in
many [14–22] but not all studies [23–27].
The aim of the present study was to evaluate whether or not
polymorphisms in TNFA and LTA were associated with
asthma, BHR and atopy in adults in two large population-
based European cohorts for which comparable methods had
been used, the Swiss Cohort Study on Air Pollution and Lung
and Heart Diseases in Adults (SAPALDIA) and the European
Community Respiratory Health Survey (ECRHS). The role of
TNF in asthma susceptibility was also evaluated across
smoking categories. Finally, the consistency of the present
results was evaluated through a meta-analysis of all published
papers on polymorphisms in the two genes.
MATERIALS AND METHODS
Study population
The present study included 11,136 subjects derived from two
different population cohorts. The ECRHS was a population-based
multicentric cohort study. In the first phase of the study, taking
place in most countries in the early 1990s, a random sample of the
population aged 20–44 yrs living in the study areas was contacted
and asked to complete a short questionnaire concerning
respiratory symptoms [28]. In a second phase, an ,20% random
subsample of the study population was contacted together with a
complementary symptom subsample. The symptom subsample
included all subjects reporting asthma-related respiratory symp-
toms in the short questionnaire who had not been selected in the
random sample [29]. Subjects in most centres were followed-up
with a median duration of follow-up of 8.9 yrs from the first
phase (ECRHS) to the second phase (ECRHS-II). For the present
analysis, the population studied consisted of 5,065 subjects with
interview information, from whom DNA had additionally been
extracted during ECRHS-II (19 centres from 10 countries).
The second cohort study population was that of the
SAPALDIA [30, 31]. SAPALDIA subjects were recruited in
1991 as a random sample of adults aged 18–60 yrs from eight
Swiss communities representing different language and
climatic regions and varying degrees of urbanisation. The
median follow-up time for SAPALDIA was 10.9 yrs.
Participants with complete interview data and DNA samples
available for genotyping were included (n56,071).
Subjects included in the present analysis could be considered
to be mainly of European-Caucasian origin. Some subjects
from Basle in Switzerland (n5400) appeared in both datasets
and were included only in the SAPALDIA analysis. Ethical
approval was obtained for each centre from the appropriate
institutional ethics committee and written consent was
obtained from each participant.
Asthma, bronchial hyperresponsiveness and atopy
The ECHRS and SAPALDIA used identical questionnaires for
the assessment of respiratory symptoms and asthma. Asthma
was evaluated at baseline (phase I of both studies) on the basis of
reported asthma symptoms and reported physician-diagnosed
asthma. The presence of asthma symptoms was based on a
positive response to either of two questions concerning: attack of
asthma during the 12 months preceding the interview, or
current use of asthma medication. Among subjects reporting
an asthma attack, 67% also reported use of asthma medication.
Alternative definitions of asthma employed in previous studies
were also examined. ‘‘Wheeze without a cold’’ was defined as a
positive response to the following two consecutive questions
(the second asked on the basis of a positive response to the first):
‘‘Have you had wheezing or whistling in your chest at any time
in the last 12 months?’’; ‘‘Have you had this wheezing or
whistling when you did not have a cold?’’ Physician-diagnosed
asthma was defined as a positive response to the following
question: ‘‘Have you ever had asthma and was this confirmed
by a doctor?’’
Data on BHR were available for a total of 8,043 subjects across
the two studies. The SAPALDIA and ECRHS used identical
spirometric protocols [28, 30], and consenting participants
underwent bronchial challenge with methacholine chloride,
administered via MEFAR1 aerosol dosimeters (Mefar,
Bovezzo, Italy) [32]. BHR was defined as a 20% fall in forced
expiratory volume in one second (FEV1) from the highest post-
diluent FEV1 during methacholine challenge with a cumulative
dose of 1 mg for both the ECRHS and SAPALDIA [33]. BHR
associated with the higher cumulative doses delivered in
SAPALDIA was not taken into account. A family history of
asthma was defined as a report of asthma of either of the
parents.
Skin-prick tests (Pharmacia & Upjohn Diagnostics, Uppsala,
Sweden) were performed in the ECRHS and SAPALDIA.
Subjects atopic at baseline in both studies were defined as
yielding positive test results to at least one common inhalant
allergen (house dust mites (Dermatophagoides pteronyssinus),
timothy grass, cat and Cladosporium herbarum).
Candidate single-nucleotide polymorphism selection and
genotyping
Two single-nucleotide polymorphisms (SNPs), TNFA -308G.A
(National Center for Biotechnology Information SNP ID
rs1800629) and LTA 252A.G (rs909253), were selected on the
basis of previous evidence of their correlation with serum levels
of TNF-a and LT-a [12, 13] and their association with asthma [14–
22]. In the SAPALDIA, the TNFA -308G.A and LTA 252A.G
polymorphisms were genotyped using a liquid-handling-assisted
set-up and a fluorescent 5’-nuclease real-time PCR (TaqMan;
Applera Europe, Rotkreuz, Switzerland) assay with an ABI Prism
7900 sequence detection system (Applied Biosystems, Rotkreuz,
Switzerland). SNP-specific primers were designed for the PCR by
Applied Biosystems (Applera Europe). The SNP-specific minor-
groove-binder probes and forward and reverse primers used
were as follows: TNFA -308G.A: 5’-CCCGTCC[C/T]CATGCC-
3’, 5’-CCAAAAGAAATGGAGGCAATAGGTT-3’, and 5’-GG-
ACCCTGGAGGCTGAAC-3’, respectively; and LTA 252A.G:
5’-CTGCCATG[A/G]TTCCT-3’, 5’-CAGTCTCATTGTCTCTGT-
CACACAT-3’, and 5’-AGAGAGAGACAGGAAGGGAACAG-3’,
respectively. A random sample of 10% of all DNA samples was
re-genotyped, and all genotypes were confirmed. The genotype
call rate was .99%.
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For the ECRHS, genotyping was performed at the Centre for
Genomic Regulation of the Spanish National Genotyping Centre
(Barcelona, Spain). SNPs were genotyped using the SNPlexTM
platform (Applied Biosystems, Foster City, CA, USA) according
to the manufacturer’s instructions and analysed on an Applied
Biosystems 3730/3730xl DNA Analyzer (Applied Biosystems,
Rotkreuz, Switzerland). Allele-calling was performed by cluster
analysis using Genemapper (version 4.0) software (Applied
Biosystems, Applera Europe). The genotype call rate was.98%.
Genotyping quality was controlled in two ways. First, internal
positive and negative controls provided by the manufacturer
were included in the reaction plates. Secondly, six duplicate
samples of two HapMap [34] reference trios were incorporated
into the genotyping process. Both genotype concordance and
correct Mendelian inheritance were verified. Genotype con-
cordance was tested using SNPator, a web-based tool for
genotyping management and SNP analysis developed by the
Spanish National Genotyping Centre [35].
The genotyping across the two laboratories that analysed
samples of the two cohorts were compared using subjects from
the centre in Basle (n5 400), who had been included in both the
ECRHS and SAPALDIA. The agreement in genotyping was
99.8%. In addition, the Basle ECRHS samples had been
previously genotyped for the TNFA -308 marker using both
restriction fragment length polymorphism and allele-specific
PCR methods [36]. Only very small differences in genotype
distribution were observed between those results and the
results reported in the present study (Chi-squared50.02;
degrees of freedom (df)52; p50.99).
Meta-analysis
Previous articles on the association of the TNFA -308G.A or
LTA 252A.G polymorphism with asthma were sought on
PubMed, and backward searches of articles cited in earlier
literature reviews or original papers were conducted. The
keywords used in the PubMed search were ‘‘asthma AND
gene AND (tumour necrosis factor OR TNF)’’ for TNFA
-308G.A and ‘‘asthma AND gene AND (lymphotoxin OR
LTA OR TNFB)’’ for LTA 252A.G.
In the meta-analysis, all studies that met the following criteria
were included: 1) design: either population-based cohort, case–
control or cross-sectional study; 2) outcome: asthma defined as
physician-diagnosed [18, 20, 23, 26, 27, 37–40] or self-reported
[16, 17, 19, 25, 29, 41, 42], regardless of age of onset; 3) ethnicity:
information available, or, if not available in the published
report, available through contact with the authors [41];
4) method of genotyping reported; 5) complete genotype
information available for subjects; and 6) genotypes in Hardy–
Weinberg equilibrium. Results from the SAPALDIA and
ECRHS were included in the meta-analysis using asthma
symptoms and physician-diagnosed asthma as the main
outcomes definition.
Statistical analysis
The statistical analysis was performed using the R genetic pack-
age (version 1.2.1) of R statistical software (version 2.4.0) [43].
Exact tests were used to test for Hardy-Weinberg equilibrium in
control subjects (subjects without asthma symptoms, physician-
diagnosed asthma, atopy or BHR) [44]. The normalised disequili-
brium constant D’ and Chi-squared p-values for marker
independence were estimated in order to determine linkage
disequilibrium between both genetic markers.
Logistic regression analysis was performed in order to
determine the adjusted associations between genotypes and
disease using co-dominant and additive models. The odds
ratio (OR) and p-values corresponding to the 95% confidence
interval (CI) were computed using the generalised linear
models procedures (glm) from the R statistical package. A p-
value of ,0.05 was considered significant. Logistic regression
models were adjusted for country (ECRHS) or study area
(SAPALDIA), sex, age, body mass index (BMI) and smoking
status. Haplotype-specific adjusted associations were also
evaluated. Haplotypes were reconstructed and analysed using
the haplo.glm function of the R library HaploStats.
The impact of population stratification in the present data was
assessed by analysing 23 unlinked SNPs (online supplemen-
tary material) using a genomic control approach [45]. These
SNPs were genotyped in the ECRHS study and in a subsample
of the SAPALDIA. The significance of the additive model was
corrected by the inflation factor (l) derived from genomic
control for each of the three main outcomes in both the ECRHS
and the pooled analysis.
Multifactor dimensionality reduction (MDR) was used on
genetic and nongenetic potential determinants jointly in order
to find genotype combinations within which the dichotomous
outcome variability was much lower than between combina-
tions [46–48]. It is an extension of the combinatorial partitioning
method and can be seen as a data reduction technique in that it
reduces the dimensionality of multilocus information to a single
dimension. The method is nonparametric, assumes no particu-
lar genetic model and generates low false-positive rates [47].
In the meta-analysis, the exact test of Hardy–Weinberg was
used to test deviations from Hardy–Weinberg equilibrium only
in control groups. ORs were estimated for each study using
Fisher’s exact test of independence for 262 (using Fisher’s
exact test for count data) tables under the prior hypothesis that
the rare allele confers susceptibility to asthma. Meta-analysis
was performed using the Mantel–Haenszel method using the
fixed effects and random effects model with R library rmeta
version 2.14. Publication bias was evaluated by measuring the
asymmetry of the funnel plot measuring the intercept from
regression of standard normal deviates against precision [49].
RESULTS
The characteristics of participants in the ECRHS and
SAPALDIA are presented in table 1. Both populations were
comparable with regard to sex, BMI and pulmonary function
(FEV1 and forced vital capacity), but not with regard to mean
age due to differences in the inclusion criteria for age. Smoking
status also differed slightly between studies, but the smoking
prevalence in the SAPALDIA is within the range observed
between different centres in the ECRHS.
The prevalence of atopy and asthma and minor allele
frequency (MAF) of TNFA -308G.A and LTA 252A.G are
shown by study and country in table 2. Asthmatics (and
consequently also atopics) were oversampled in the ECRHS
since the subcohort with respiratory symptoms was included.
Among the random samples of the ECRHS and SAPALDIA,
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the prevalence of atopy ranged from 15% in Germany (ECRHS)
to 42% in Australia (ECRHS). The prevalence of asthma
symptoms ranged from 2% in Germany, Estonia, Spain and
Belgium to 7% in the UK and Australia. Even higher
prevalences were reported for physician-diagnosed asthma.
Geographical differences were also observed for the MAFs of
both polymorphisms. The lowest MAFs were observed in France
(12% for TNFA -308G.A and 27% for LTA 252A.G) and the
highest in the UK (21% for TNFA -308G.A and 41% for LTA
252A.G). The two polymorphisms were in strong linkage
disequilibrium (Chi-squared57516.29; D’50.98; r250.60;
p,2.22610-16). The genotype distribution for both alleles was
consistent with the Hardy–Weinberg equilibrium in the control
group (p.0.05), except for the French ECRHS centre in Grenoble
(p,0.001). The analyses presented in the current article include
data from Grenoble. The results were only minimally modified
when all of the analyses were repeated excluding this centre (data
not shown). No strong effects of population stratification were
detected in the present sample, obtaining l of ,1 (1.05 in atopy,
1.06 in asthma and 1.30 in BHR).
The associations of TNFA -308G.A with atopy, asthma
symptoms and BHR adjusted for country (ECRHS) or centre
(SAPALDIA), sex, age, BMI and smoking status are sum-
marised in table 3. A significant association was found for
asthma symptoms and TNFA -308GA heterozygotes (OR51.38;
p50.001) and for the TNFA -308A allele (OR51.30; p50.002).
An analysis of TNFA -308G.A by study showed an increased
risk of asthma symptoms in the ECRHS but not in the
SAPALDIA (tables 3 and 4; fig. 1). The result of the test for
heterogeneity between the two studies was significant (Q-
statistic 5.92; df51; p50.015). In the ECRHS, a significant risk
increase for asthma symptoms was observed for the GA and
AA genotypes and the A allele (OR51.49; p56.3610-5).
Stratification by country in the ECRHS showed no differences
in risk (Q52.66; df58; p50.95; table 4; fig. 1) and an increased
risk (OR.1) was observed for all countries. ORs for the random
subsample of the ECRHS tended to be lower than those of the
asthma-enriched subsample (data not shown). In the
SAPALDIA, no difference in effect of TNFA -308G.A was
observed between Latin- and German-speaking regions
(Q50.44; df51; p50.51). Exclusion of SAPALDIA subjects
who were aged .45 yrs at baseline (so as to compare with a
similar population structure as in the ECRHS) did not affect the
risk estimates for asthma. The OR for the A allele in all
SAPALDIA subjects was 0.94 (p50.71), whereas the OR for
SAPALDIA subjects aged ,45 yrs was 0.89 (p50.57). The
observed associations between TNFA -308G.A and asthma
symptoms were not modified by either sex or atopy. In both the
ECRHS and SAPALDIA, TNFA -308G.A was associated with a
slight increase in BHR prevalence (A allele OR51.15; p50.03),
with similar risks found in the two studies (A allele OR51.13
and 1.18, respectively). No significant association was found for
TNFA -308G.A with atopy (table 3). The ORs for the random
subsample of the ECRHS tended to be lower than those of the
asthma-enriched subsample (data not shown).
The strength of the association of TNFA -308G.A genotypes
was different for distinct asthma-related phenotypes. ORs for
the A allele and for distinct phenotypes are shown in table 5. A
positive association was found for most, but not all, pheno-
types examined, although the differences between ECRHS and
SAPALDIA remained with regard to phenotypes based on
reported asthma symptoms.
Results for LTA 252A.G are summarised in table 6. Overall,
ORs tended to be lower than for TNFA -308G.A. A
significantly increased risk of asthma symptoms was observed
for the heterozygous GA genotype (OR51.21; p50.05), which
TABLE 1 Characteristics of participants in the European Community Respiratory Health Survey (ECRHS) and Swiss Cohort Study
on Air Pollution and Lung and Heart Diseases in Adults (SAPALDIA) at baseline
Both cohorts ECRHS SAPALDIA
Symptom sample Random sample Age 18–44 yrs All ages
Subjects n 10736 796 3869 3572 6071
Males % 49 44 48 50 50
Age yrs 38¡10 34¡7 34¡7 33¡8 41¡11
BMI kg?m-2 23.9¡3.8 25.1¡4.8 23.9¡3.7 23.1¡3.4 23.8¡3.6
Smoking status %
Never-smoker 45.5 42.7 43.5 48.0 47.1
Ex-smoker 22.4 18.6 21.7 19.6 23.3
Current smoker 32.1 38.7 34.7 32.5 29.6
Asthma symptoms % 5.6 35.8 3.7 2.9 2.9
Physician-diagnosed asthma % 8.8 38.7 6.7 6.2 6.2
Atopy % 21.5 48.4 24.7 22.9 19.8
FEV1 % pred 106.6¡14.6 100.3¡16.4 105.8¡13.3 107.1¡13.4 107.8¡14.9
FVC % pred 112.3¡14.9 107.4¡14.3 109.2¡13.1 112.3¡13.9 114.9¡15.5
BHR % 12.5 37.8 11.7 9.2 9.9
Data are presented as mean¡SD unless otherwise indicated. BMI: body mass index; FEV1: forced expiratory volume in one second; FVC: forced vital capacity; BHR:
bronchial hyperresponsiveness; % pred: % predicted.
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was primarily driven by an association of the G allele with
asthma in the ECRHS sample (OR51.22; p50.01).
Haplotype analysis
The 252G/-308A haplotype was positively associated with
asthma symptoms (OR51.29; p50.003) compared to the most
common haplotype, 252A/-308G. The prevalence of the
252A/-308A haplotype was ,0.01 and could, therefore, not
be tested for an association with asthma. No significant overall
results were found for the 252G/-308G haplotype (online
supplementary material).
Smoking effect
An association of TNFA -308G.A (GA and AA genotypes
compared to GG genotype) with asthma was significant among
never-smokers (OR51.33; p50.03) and ex-smokers (OR51.64;
p50.01), whereas a nonsignificant excess risk was found for
current smokers (OR51.20). This differential effect was only
observed in the ECRHS and not in the SAPALDIA. In the
ECRHS, the effect of TNFA -308G.A was significant among
never-smokers (OR51.50; p50.01) and ex-smokers (OR52.36;
p50.0009). However, the p-value for interaction was nonsigni-
ficant when examining never- versus ever-smokers (p50.52) or
smoking status in three categories (p50.23).
Multifactor dimensionality reduction
In the nonparametric MDR analysis, multiple genetic loci and
environmental exposures associated with asthma were
detected simultaneously in the absence of a main effect. An
increasing number of interactions was examined, starting from
including singular effects up to three-way interactions, and the
best fit of each combination of variables was tested through
permutation tests using 5,000 replications. Among the seven
variables examined, significant results were found for a model
including LTA 252A.G, smoking and region (with 5,000
permutations, permutation-based p-value of ,0.001). The best
fit was for a model with two variables included, smoking and
region (permutation-based p-value of ,0.001).
Meta-analysis
The meta-analysis of TNFA -308G.A was performed includ-
ing the country-specific results from ECRHS countries and the
two region-specific results from the SAPALDIA as individual
observations along with the 16 published studies listed in
table 4 and figure 1. The funnel plot for publication bias was
not asymmetric (p.0.10), suggesting a lack of publication bias
in the present meta-analysis. The ECRHS and SAPALDIA
results were based on asthma symptoms. In total, 4,341 cases of
asthma and 13,459 controls were examined (table 4; fig. 1). The
combined OR for asthma using a fixed-effects model was
1.32 (p,0.001) and using a random-effects model 1.35
(p50.001). Similarly to a previous meta-analysis [37], signifi-
cant heterogeneity was observed between the Caucasian
populations (Q556.57; df517; p,0.001). Excluding the study
of ALBUQUERQUE et al. [26], which had an MAF of 31% that was
different from all other studies, and the study of SHIN et al. [27],
with a different MAF to other Asian population studies (17%),
the heterogeneity diminished considerably (Q59.64; df515;
p50.84). The combined OR in Caucasian populations after the
exclusion of the study of ALBUQUERQUE et al. [26] was 1.24
(p,0.0001) for the fixed-effects model and 1.29 (p50.001) for
the random-effects model. Heterogeneity was nonsignificant in
Asian populations, although the ORs for a study in Korea [27]
were markedly different from those of all other studies. The
same risk was observed when physician-diagnosed was
included instead of asthma symptoms in the meta-analysis,
TABLE 2 Symptom prevalence at baseline and minor allele frequency (MAF) by study site
Study Country Sample
size n
Atopy % Asthma
symptoms %
Physician-diagnosed
asthma %
BHR % MAF#
TNFA -308G.A LTA 252A.G
ECRHS All 4665 (3869) 29 (25) 9 (4) 12 (7) 16 (12) 0.16 0.32
Norway 436 (436) 23 (23) 3 (3) 8 (8) 8 (8) 0.19 0.36
Sweden 643 (457) 41 (30) 2 (6) 21 (8) 19 (8) 0.15 0.37
UK 358 (289) 39 (34) 18 (7) 20 (8) 23 (17) 0.21 0.41
Australia 341 (248) 49 (42) 21 (7) 26 (13) 28 (21) 0.14 0.28
Estonia" 228 (175) 22 (18) 4 (2) 5 (3) 0.15 0.29
Germany 439 (439) 15 (15) 2 (2) 4 (4) 14 (14) 0.15 0.33
Belgium 506 (455) 27 (24) 5 (2) 7 (5) 13 (9) 0.18 0.32
France 549 (522) 28 (28) 7 (5) 13 (11) 14 (12) 0.12 0.27
Spain 1165 (848) 22 (19) 6 (2) 9 (4) 13 (1) 0.15 0.29
SAPALDIA All 6071 19.8 2.9 9.9 6.2 0.139 0.305
German+ 3308 19.7 2.9 9.8 6.6 0.137 0.307
Latin1 2763 19.9 2.8 10 5.7 0.141 0.303
Data shown in parentheses represent the prevalences in the European Community Respiratory Health Survey (ECRHS) random sample. SAPALDIA: Swiss Cohort Study
on Air Pollution and Lung and Heart Diseases in Adults. BHR: bronchial hyperresponsiveness; TNFA: tumour necrosis factor-a gene; -308G.A: guanine to adenine
substitution of nucleotide -308; LTA: lymphotoxin-a gene. #: in control subjects without asthma symptoms, physician-diagnosed asthma, cough, phlegm, current wheeze
or atopy; ": atopy measured using specific immunoglobulin E (no skin-prick test available) and BHR not measured; +: German-speaking centres: Basle, Aarau, Davos,
and Wald; 1: Italian- or French-speaking centres: Lugano, Payerne, Geneva and Montana.
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with an OR of 1.27 (p,0.001). A meta-analysis of 10 previous
studies on LTA 252A.G and asthma [14, 17, 19, 20, 25–27, 38,
40, 41, 42] was also performed, including the data from the
present study. The meta-analysis examined a total of 3,120
cases and 12,026 controls, with the combined OR being 1.01
(95% CI 0.99–1.16; p50.06) for the fixed-effects model and 1.08
(95% CI 0.95–1.23; p50.22) for the random-effects model.
DISCUSSION
A genetic association study on the TNFA -308G.A and LTA
252A.G polymorphisms with asthma and related phenotypes
was performed in two large European prospective cohorts.
This is the largest association study of TNFA -308G.A/LTA
252A.G in subjects well phenotyped for atopy and respiratory
symptoms using validated questionnaires and measures of
lung function, BHR and atopy. A moderate but significant
association of the TNFA -308GA genotype and the TNFA -308A
allele with increased asthma risk was found. The risks for BHR
were also increased but to a lesser extent, whereas no
consistent associations were found for atopy. The present
results were verified using alternative nonparametric analyses
and a meta-analysis of all published studies. Weaker associa-
tions were found for LTA. The effects of TNFA can be
attributed to linkage disequilibrium with other asthma genes,
to a main effect of TNFA or to an interaction and modification
of the effect by environmental exposures.
The two polymorphisms examined are located in the MHC
class III region, near human leukocyte antigen (HLA)-B [5].
The TNFA -308A allele is in strong linkage disequilibrium with
the HLA-A1, -B8 and -DR3 alleles [12], which are also
associated with higher levels of TNFA -308G.A [50].
Although some studies suggest that the LTA 252A.G/TNFA
-308G.A association is independent of MHC class II alleles
[21, 42], MOFFAT et al. [14] found that two haplotypes contain-
ing the TNFA -308A allele (LTA 252G/TNFA -308A/HLA-
DRB1*3 and LTA 252G/TNFA -308A/HLA-DRB1*2) were
more strongly associated with asthma and BHR than other
haplotypes containing only LTA 252A.G/TNFA -308G.A
polymorphisms. Identification of the individual effects of LTA
252A.G and TNFA -308G.A is difficult due to the linkage
disequilibrium. The present results indicate that TNFA
-308G.A is associated with several asthma-related pheno-
types, whereas less consistent results were observed for the
main effects of LTA 252A.G. Haplotype analysis showed that
only the model with the TNFA -308A allele was associated with
asthma, and that this association was equivalent to the model
with TNFA -308G.A alone. This evidence suggests that the
associations observed for LTA 252A.G in asthma and BHR
may be due to its linkage with TNFA -308G.A.
TNF-a is a potent pro-inflammatory cytokine found in high
concentrations in bronchoalveolar fluid from asthmatics [8, 9,
51]. TNFA nucleotide -308 is located in the promoter region of
TNFA, and in vitro studies have reported increased TNFA
transcription associated with the TNFA -308G.A variant [12,
52]. The A allele has been associated with increased expression
[12] and secretion of TNF-a [52, 53], although this association is
not uniformly supported [54, 55]. No association of the TNFA
A allele with atopy was observed, whereas it was observed for
asthma symptoms and BHR. Furthermore no modification of
the association of TNFA -308G.A and asthma by atopic status
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was observed. One study [20] reported that TNFA -308G.A
was a risk factor for atopic asthma but not for nonatopic
asthma, although a number of other studies did not find this
interaction [23, 27, 42].
In the present study, the pattern of the interaction between
TNF polymorphisms and tobacco smoke was not clear. TNF-a
is central to acute cigarette-smoke-induced inflammation and
the resulting connective tissue breakdown. Oxidative stress
involved in inflammation is partly regulated by cytokines such
as TNF-a. TNFA -308G.A effects on the inflammatory
response to oxidative stress have been suggested in other
studies in relation to exposure to ozone, occupational
endotoxin and environmental tobacco smoke, but the results
have been inconsistent. Interaction of the LTA 252A.G and
TNFA -308G.A polymorphisms with environmental factors
has been shown in several studies in relation to smoking,
ozone and other environmental or occupational exposures,
although the results have not been consistent [56-59].
The present study had low power for the evaluation of
differences between countries and regions due to the low MAF
of the TNFA -308A allele. No effect of population stratification
was observed in the present sample, although the number of
markers tested might be insufficient for the detection of lower
stratification between European populations [60]. The associa-
tion analyses of both markers revealed differences in risk
between the ECRHS and SAPALDIA cohorts for asthma
symptoms, whereas more consistent results were obtained
for BHR and atopy. The study protocols of both studies were
similar, and phenotypes were defined using the same ques-
tions. Nevertheless, differences across the two cohorts tended
to relate primarily to asthma phenotypes, defined by ques-
tionnaire, rather than to phenotypes derived from functional or
TABLE 4 Tumour necrosis factor-a gene guanine to adenine (A) substitution of nucleotide -308 polymorphism and asthma
symptoms in the studies used for the meta-analysis and study weighting
First author [ref.] Year Population Case/control A allele n Weight %
Present study
ECRHS 2007 Norway 6/135 2.10
Sweden 54/140 5.07
Estonia 5/62 1.57
UK 33/116 4.15
Australia 24/77 3.94
Germany 3/121 1.20
Belgium 9/144 2.78
France 14/118 3.66
Spain 18/287 3.91
SAPALDIA 2007 Switzerland 47/1629 5.44
Present overall 213/2829 33.82
Previous studies
LOUIS [23] 2000 European Caucasian 31/31 3.70
BUCKOVA [25] 2002 Czech 51/40 4.54
WINCHESTER [16] 2000 British and Irish 13/150 2.69
BILOLIKAR [38] 2005 British 61/43 3.52
MUNTHE-KAAS [22] 2007 Norway 130/213 5.59
ALBUQUERQUE [26] 1998 Australian Caucasian 58/25 3.44
MOFFATT [42] 1997 Australian 52/113 4.79
EL BAHLAWAN [41] 2003 African American from USA 9/53 2.30
WITTE [40] 2002 USA 75/67 5.03
WANG [20] 2004 Taiwanese 18/53 3.69
SANDFORD [17] 2004 Chinese 26/16 3.29
SHIN [27] 2004 Korean 54/41 4.52
AOKI [37] 2006 Japanese 21/12 2.77
HONG [39] 2007 Korean 92/14 2.77
WINCHESTER [16] 2000 South Asian 2/39 0.49
GUPTA [18] 2005 Indian 42/34 4.13
SHARMA [19] 2006 North India 66/37 4.53
SHARMA [19] 2006 West India 55/36 4.39
Previous overall 856/1017 66.18
Overall Total 1069/3846 100
ECRHS: European Community Respiratory Health Survey; SAPALDIA: Swiss Cohort Study on Air Pollution and Lung and Heart Diseases in Adults.
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biological tests. However, a study assessing the internal
consistency of respiratory symptoms suggests that interna-
tional comparisons are not affected by errors due to cross-
cultural variations in the reporting of symptoms [61]. The
major difference between the two studies was the inclusion in
the ECRHS of a subsample with subjects that reported
respiratory symptoms in the initial screening questionnaire.
This subsample represented .60% of the asthma cases in the
ECRHS and led to differences in symptom prevalences
compared to the SAPALDIA. The magnitude of asthma risk
in relation to TNFA genotypes in the ECRHS after exclusion of
the asthma-enriched sample tended to be to weaker, although
still positive, indicating that inclusion of the asthma-enriched
sample could not explain the differences in risk between the
two studies. The slightly stronger association observed in the
oversampled asthmatics from the ECRHS might, possibly,
reflect an underlying stronger effect of the TNFA -308G.A
genotype in more severe forms of asthma and in asthma
persistence as well as progression. There is, however, only very
limited evidence supporting such an association [15, 62]. Other
potential differences, such as errors in genotyping, could be
disregarded. Given the above, the most likely explanation for
the absence of an association with self-reported asthma
phenotypes in the SAPALDIA is the lack of statistical precision
due to a much lower number of cases compared to the ECHRS.
The meta-analysis of all published studies reinforces the
present results of a positive association between the TNFA
-308G.A genotype and asthma prevalence, although some
geographical variability could be observed. An inverse
association was observed in only two studies [26, 27].
However, the combined estimate confirms the association of
TNFA -308G.A with an increased risk of asthma in European
and Asian populations. Population stratification is a concern in
large genetic association studies with heterogeneous popula-
tion [60]. The subjects in the present analysis were almost
entirely of European ancestry. However, even within the
present study population, differences in allelic frequency were
observed between countries, with higher MAFs obtained in the
UK. The two previous studies that found an inverse association
with asthma risk [26, 27] were outliers with regard to TNFA
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FIGURE 1. Meta-analysis of tumour necrosis factor-a gene guanine to adenine
(A) substitution of nucleotide -308 polymorphism and asthma symptoms, including
the European Community Respiratory Health Survey (ECRHS) and Swiss Cohort
Study on Air Pollution and Lung and Heart Diseases in Adults (SAPALDIA). Data are
presented as A allele odds ratio (OR; & (size reflects weighting)) for asthma
symptoms and 95% confidence interval (CI; horizontal bars). The centres of the
diamonds indicate the combined mean effect of the studies and their extremities
the 95% CI; ……: line of no effect. The arrowheads indicate the positions of ORs of
low weight. #: British and Irish; ": South Asian; +: North India; 1: West India.
TABLE 5 Adjusted association of tumour necrosis factor-a gene -308 adenine allele with various asthma-related phenotypes and
their combinations in the two cohorts
Both cohorts ECRHS SAPALDIA
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
Atopy 0.97 (0.88–1.07) 0.51 0.98 (0.86–1.13) 0.82 0.96 (0.84–1.09) 0.50
Asthma symptoms 1.30 (1.11–1.53) 0.001 1.49 (1.23–1.81) 5.6610-5 0.94 (0.69–1.29) 0.71
BHR 1.16 (1.02–1.32) 0.03 1.14 (0.95–1.36) 0.16 1.18 (0.98–1.41) 0.09
Physician-diagnosed asthma 1.13 (0.98–1.29) 0.09 1.37 (1.15–1.63) 0.0004 0.84 (0.67–1.05) 0.12
Asthma symptoms and atopy 1.25 (1.02–1.54) 0.03 1.41 (1.12–1.78) 0.003 0.78 (0.47–1.29) 0.33
Asthma symptoms and BHR 1.25 (0.98–1.61) 0.07 1.30 (0.98–1.73) 0.068 1.05 (0.62–1.77) 0.86
Wheeze without a cold 0.97 (0.85–1.09) 0.58 1.01 (0.86–1.18) 0.92 0.90 (0.72–1.11) 0.31
Models are adjusted by age, sex, body mass index, country (European Community Respiratory Health Survey (ECRHS)) or study centre (Swiss Cohort Study on Air
Pollution and Lung and Heart Diseases in Adults (SAPALDIA)) and smoking status. OR: odds ratio; CI: confidence interval; BHR: bronchial hyperresponsiveness.
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-308A allele frequency. In the present meta-analysis, large
variation in the allelic frequency of the TNFA -308A allele was
observed between populations, with lower frequencies in those
from Korea, Japan, China and Taiwan. One limitation of the
present meta-analysis is that the selection criteria were broad,
leading to the inclusion of different age groups and definitions
of asthma (e.g. paediatric asthma, adult asthma and atopic
asthma), and the biological mechanisms involved in each of
these asthma-related phenotypes might be different. This is
particularly important given the differences in risk observed
for different asthma phenotypes in the present study. Since
there are limited published data on BHR, it was not possible to
perform a meaningful meta-analysis for this end-point.
Conclusions
In the present large international population-based prospective
study, the tumour necrosis factor-a gene guanine to adenine
substitution of nucleotide -308 polymorphism was associated
with a moderately increased risk of asthma and bronchial
hyperresponsiveness, whereas no association was found for
atopy. These results were supported by a meta-analysis of the
published evidence.
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